Affordable Access

deepdyve-link
Publisher Website

Management of Pituitary Adenomas: Mononostril Endoscopic Transsphenoidal Surgery.

Authors
  • Darwish, Houssein1, 2
  • El-Hadi, Usamah3
  • Haddad, Georges4
  • Najjar, Marwan4
  • 1 Department of Neurosurgery, School of Medicine, University of Virginia System, Charlottesville, USA.
  • 2 Department of Neurosurgery, Bahman Hospital, Tehran, Iran. , (Iran)
  • 3 Department of Otolaryngology- Head & Neck Surgery, Faculty of Medicine, American University of Beirut, Beirut, Lebanon. , (Lebanon)
  • 4 Department of Surgery, Division of Neurosurgery, Faculty of Medicine, American University of Beirut, Beirut, Lebanon. , (Lebanon)
Type
Published Article
Journal
Basic and clinical neuroscience
Publication Date
Jan 01, 2018
Volume
9
Issue
2
Pages
121–128
Identifiers
DOI: 10.29252/nirp.bcn.9.2.121
PMID: 29967671
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The endoscopic transsphenoidal approach for pituitary adenomas and other sellar lesions is quickly becoming the procedure of choice in their surgical management. The most common approach is binostril three-hand technique which requires a large exposure and subjects both nasal cavities to potential trauma. To reduce nasal morbidity, we employ a mononostril two-hand technique with the help of the endoscope holder. In this research, we review our series to determine efficacy of this approach in the management of pituitary adenomas. We performed a retrospective analysis of our initial series of 64 consecutive patients with pituitary adenomas operated by the same surgical team from 2008 till 2014 using a mononostril endoscopic approach. After categorizing the lesions into microadenomas, noninvasive macroadenomas, and invasive macroadenomas, we reviewed the radiological and biochemical outcomes of the surgeries after 3 months, 12 months, and 18 months. We also assessed recurrences and complications. Extent of resection was divided into gross total resection, near total resection (>90% resection), and partial resection for the remaining. Our results show resection rates comparable to most series in the literature, with a gross total resection of 87% in non-invasive macroadenomas, and surgical disease control in 75% of invasive nonfunctioning adenomas. The remission rate in Cushing's disease was 81%, where it achieved up to 58% surgical remission in growth hormone secreting pituitary adenomas (including the invasive adenomas). The complication rate was very low. We conclude that the mononostril endoscopic approach is well suited for most pituitary tumor operations and carries comparable remission and resection rates to most endoscopic series with minimal complications and nasal morbidity.

Report this publication

Statistics

Seen <100 times